Evidence map›Paper›PMID 38797856›Full record

ArticleJournal of translational medicine2024

Revisiting the role of pregnancy zone protein (PZP) as a cancer biomarker in the immunotherapy era.

Jie Huang, Ying Xu, Yidan Chen, Juan Shen, Yao Qiu, Xin Li, Xueqin Chen, Shenglin Ma

Abstract readLetter
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jie HuangDepartment of Oncology, Hangzhou Cancer Hospital, No.34 Yanguan Lane, Shangcheng District, Hangzhou, 310002, China.
Ying XuThe Forth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Yidan ChenCancer Research Institution, Hangzhou Cancer Hospital, Hangzhou, 310002, China.
Juan ShenDepartment of Oncology, Hangzhou Cancer Hospital, No.34 Yanguan Lane, Shangcheng District, Hangzhou, 310002, China.
Yao QiuDepartment of Oncology, Hangzhou Cancer Hospital, No.34 Yanguan Lane, Shangcheng District, Hangzhou, 310002, China.
Xin LiDepartment of Oncology, Hangzhou Cancer Hospital, No.34 Yanguan Lane, Shangcheng District, Hangzhou, 310002, China.
Xueqin ChenDepartment of Oncology, Hangzhou Cancer Hospital, No.34 Yanguan Lane, Shangcheng District, Hangzhou, 310002, China.
Shenglin MaDepartment of Oncology, Hangzhou Cancer Hospital, No.34 Yanguan Lane, Shangcheng District, Hangzhou, 310002, China. mashenglin@medmail.com.cn.

Funding

Hangzhou Health Science and Technology Plan project A20220840Zhejiang Provincial Medical Health Science and Technology Plan 2023557997
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorImmunotherapyNeoplasmsFemaleHumansPregnancy ProteinsBiomarkers, TumorPregnancy Proteins

Identifiers

PMID38797856
PMCPMC11128099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.